Nerium Biotechnology Stock

Nerium Biotechnology engages in the development of oleander-based products for the treatment of proliferative diseases and viral infections.

About Nerium Biotechnology Stock

Nerium Biotechnology, Inc., a biotechnology company, engages in the development of oleander-based products for the treatment of certain forms of proliferative diseases and viral infections. Its lead product includes Anvirzel, which is used to treat various forms of cancer. The company’s product line also comprises HIviral for the treatment of HIV/AIDS; HEP-viral for the treatment of hepatitis C; and NeriumAD, a skin cream for age-defying treatment. Nerium Biotechnology, Inc. is based in San Antonio, the United States.

Funding History

March 2011	$289K

Management

Director

John F. O'Donnell

CEO & Chairman of the Board of Directors

Dennis Ray Knocke

CFO

Joseph B. Nester

Other Companies

Learn More

Baebies

Newborn Screening and Pediatric Testing

Relievant provides patients with low risk therapy that affords the ability to alleviate their back pain.

SigTuple builds intelligent solutions for medical diagnosis using state of the art machine learning techniques.

Develops innovative medicines for women's health and endocrine disorders

5Age (years)

$70.0MTotal Funding

EquityZen does not have an affiliation with, formal relationship with, or endorsement from Nerium Biotechnology or any companies feature above. This profile is based on publicly available information and is intended to be informative in nature.

Some data provided by Crunchbase

Trending Companies

Join 180K+ Investors and Shareholders

On our trusted digital marketplace for private companies

EquityZen Recognized As:

Why EquityZen?

EquityZen helps investors to access private companies and their employees to sell shares.

Investment opportunities posted on this website are "private placements" of securities that are not publicly traded, are subject to holding period requirements, and are intended for investors who do not need a liquid investment. Investing in private companies may be considered highly speculative and involves a high degree of risk, including the risk of substantial loss of investment. Investors must be able to afford the loss of their entire investment. See our Risk Factors for a more detailed explanation of the risks involved by investing through EquityZen’s platform.

EquityZen Securities LLC (“EquityZen Securities”) is a subsidiary of EquityZen Inc. EquityZen Securities is a broker/dealer registered with the Securities Exchange Commission and is a FINRA/SIPC member firm.

Equity securities are offered through EquityZen Securities. Check the background of this firm on FINRA’s BrokerCheck.

EquityZen.com is a website operated by EquityZen Inc. ("EquityZen"). By accessing this site and any pages thereof, you agree to be bound by our Terms of Use.
EquityZen and logo are trademarks of EquityZen Inc. Other trademarks are property of their respective owners.
© 2020 EquityZen Inc. All rights reserved.